cor2ed
engage checkpoint medical linkedin twitter
bg

Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?

Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?

Asst. Prof. Joleen Hubbard, Assoc. Prof. Yu Sunakawa

Ass. Prof. Joleen Hubbard and Ass. Prof. Yu Sunakawa discuss the Clinical Question: Which targeted drug is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Portrait of Joleen Hubbard
Asst. Prof. Joleen Hubbard

Medical Oncologist

Mayo Cinic Rochester

United States (US)

Portrait of Yu Sunakawa
Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

preview next

time Expert View | open 5 min | 2017

download resources

I agree that this educational programme:

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Other programmes developed by Asst. Prof. Joleen Hubbard

Other programmes developed by Assoc. Prof. Yu Sunakawa